STOCKS TELEGRAPH

Author: ST Staff

  • Why is Two Harbors Investment Corp. (TWO) stock rising in Pre-Market today?

    Why is Two Harbors Investment Corp. (TWO) stock rising in Pre-Market today?

    Shares of the Two Harbors Investment Corp. (TWO) stock were rising in the Pre-Market trading session today on June 17, 2021, following the news that Cardtronics plc (NASD: CATM) will be replaced by Two Harbors Investment Corp in the S&P SmallCap 600 before the opening of the trading session on Tuesday, June 22, 2021. TWO stock prices saw a push of 4.53% to reach $7.84 a share as of this writing. The stock went up by 0.54% at the previous closing. Let’s deep dive to explore more of it.

    What’s Happening?

    Two Harbors Investment Corp, founded in 2009, is working as an agency as well as a real estate investment trust(REIT). It seems that the TWO stock is continuing the previously built rising momentum in the stock market. The replacement of Two Harbors Investment Corp with CATM in the S&P SmallCap 600 is the key trigger behind this rising stock price. As NCR Corp. (NYSE: NCR) has already signed an acquisition agreement with Cardtronics, the acquisition is expected to be complete soon after customary closing conditions.

    First Quarter 2021 Financial Results:

    Back to the previous month on May 5, 2021, TWO stocks did announce the first quarter 2021 financial results according to which.

    • Two Harbors Investment Corp recorded a book value of $7.29 per common share which represents a 2.2% quarter-based return on book value.
    • Roughly $48.5 million income was generated in the recently reported quarter which represents a 9.3% annualized return on average common equity.
    • Core earnings for the TWO stock were $45.8 million in the first three months of 2021.
    • TWO stock announced a $0.17 per share dividend in the first quarter of 2021.

    Efforts for Optimized liability and Capital Structure:

    • Two harbors issued 5-year convertible seniors notes worth $287.5 million.
    • $143.7 million principal amount of convertible senior notes due 2022 had been repurchased and retired by Two Harbors Investment Corp.
    • Redemption of $75 million and $200 million series D and E respectively preferred shares had been completed by Two stock.
    • The funding capacity of Two Harbors Investment Corp had been expanded via the closing of a $300 million MSR asset financing facility.

    Conclusion:

    TWO stock is hot among investors as far as market sentiment is concerned but every rise is followed by the fall and vice versa as the stock market is unpredictable. So, investors need to know the nitty-gritty of the stock before making any decision.

  • Creative Realities, Inc. (CREX) Stock Shoots Up as Latest Target of Meme Stock Phenomenon Taking Over Stock Markets

    Creative Realities, Inc. (CREX) Stock Shoots Up as Latest Target of Meme Stock Phenomenon Taking Over Stock Markets

    Creative Realities, Inc. (CREX) stock prices shot up by a significant 15.28% as of the market closing on June 16th2021, bringing the price per share up to USD$2.49 at the end of the trading day. Subsequent premarket fluctuations have seen the stock marginally dip by 0.80%, bringing it down to USD$2.47.

    Meme Stock Phenomenon

    A plethora of stocks have recently been the targets for a coordinated pump and dump by the Reddit-driven retail investors in what has come to be known as the meme stock phenomenon. In the absence of recent news or any fundamental developments, companies sometimes on the brisk of collapse find themselves renewed by the sweeping meme stock craze. CREX seems to be the latest target of the meme stock madness, with the sudden and sharp overnight increase in equity value coming despite a stark lack of news or fundamental developments.

    Gross Profits

    Gross profit for the quarter ended March 31st, 2021 was reported at USD$2.2 million, representing a 39% increase from the gross profit reported for the same quarter of the prior year. Almost half of the USD$0.6 million difference is largely attributable to a period-over-period increase in revenue, with the other half being driven by higher gross profit generated from the sale of Thermal Mirror and Safe Space products.

    Net Income Reports

    Net income for the quarter ended March 31st, 2021 was reported at USD$1.3 million, up from the USD$13.2 million net loss reported for the same quarter of the prior year. This rebounding is largely attributable to a USD$0.3 million increase in the fair value of debt instruments, as well as a USD$1.5 million increase associated with gains on settlement of obligations. At the forefront of these settlements is the forgiveness of the company’s PPP loan for the quarter.

    Registered Direct Offering

    February 18th, 2021 saw the company enter into a securities purchase agreement with institutional investors. As per the agreement, CREX would sell 800,000 shares of its common stock in a registered direct offering, with a price per share of USD$2.50. The net proceeds generated from the offering came out to USD$1.8 million after the deduction of expenses related to the offering.

    Future Outlook for CREX

    Armed with the fortuitous surge in value of their equity, CREX is poised to capitalize on the opportunities presented to it. The company is keen to continue its trajectory of success and usher in more organic growth over the long term. Current and potential investors are hopeful that the management will leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • Uxin Limited (UXIN) Stock Prices Plummets Following Financing Transaction Announcement

    Uxin Limited (UXIN) Stock Prices Plummets Following Financing Transaction Announcement

    Uxin Limited (UXIN) stock prices were down by a significant 12.64% as of market close on June 21st, 2021, bringing the price per share down to USD$3.94 at the end of the trading day. Subsequent pre-market fluctuations saw the price fall sharply by an additional 5.58% to hit USD$3.72.

    USD$315 Million Financing Transaction

    June 15th, 2021 saw the company announce the entering into definitive agreements with NIO Capital and Joy Capital, who will invest a total of up to USD$315 million in UXIN as per the terms of the agreements. The company has concurrently agreed with current holders of convertible notes to convert notes in an aggregate principal amount of USD$69 million into Class A ordinary shares.

    Transition to Inventory-Owning Model

    Almost the entirety of the transaction volume sold over the course of Q4 2020 was done so from the company’s own inventory, marking the culmination of the transformation into an inventory-owning business model. To facilitate this move and maintain standards of quality, UXIN has started construction in Xi’an for its first inspection and reconditioning center.

    Preferential Government Policies

    The company has seen massive growth in the potential of the Chinese used car market, primarily driven by the facilitation of that growth with preferential policies from the Chinese government. An example of such a change is the reduction of VAT from 2% to 0.5% on used car sales. Restrictions from before were recently lifted across all regions as per a mandate of the General Office of the State Council. Chief among these was the restriction on cross-regional transactions and title transfers of used cars.

    Transactions Facilitate by Changed Policies

    Another such facilitation of accessibility in the used car market is the simplification of the documentation process, which has been completely digitized. Reductions in title transfer costs and the increase in the efficiency of cross-regional used car transactions has further bolstered UXIN.

    Strategic Partnership with JD.com

    UXIN recently announced the launching of its partnership with JD.com to launch a self-operated online store for used car transactions through the partner’s proprietary online platform. This move serves to provide customers with a one-stop shop for their online used car purchasing and selling needs. In order to provide unparalleled consumer experiences, the collaborative platform will provide users with car inspection, purchasing, insurance, and aftersales services solutions.

    Future Outlook for UXIN

    UXIN has recently established impressive financial results, and it has formed strategic partnerships with big-name companies, granting it a competitive edge in the used car market. The company is keen to recover from the recent suffering of its equity value. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • Why Did HMBL Stock Gain 11%?

    HUMBL Inc (OTCPink: HMBL) has risen by 11.53% at previous close to $1.32. A price range of $1.11 and $1.34 was seen for HUMBL stock. In the absence of news, HMBL stock rose, so we can look back at recent developments to gain a deeper perspective on the company.

    How did things go recently at HMBL?

    In terms of mobile payments, ticketing, and NFTs, HUMBL facilitates simplifying and packaging new technologies such as blockchain. HMBL is a digital money platform that enables consumers and merchants to pair digital payments.

    In the digital economy, HMBL offers HUMBLPAY to connect consumers and retailers worldwide to share and pay. By connecting merchant shops, deal listings, affiliate programs, and web checkout integrations with HUMBL Pay, HUMBLMARKETPLACE enables global commerce.

    This month, HUMBL acquired Tickeri, an international ticketing platform focused on Latin markets.

    • For a total of $20M USD, a blend of debt and common stock was used to purchase the acquisition.
    • In addition to ticketing, peer-to-peer remittances, and mobile payments, HMBL will be expanding its international reach by offering these services on top of the existing Tickeri platform.
    • Mobile payments, tickets, and NFTs are on the brink of convergence.
    • HMBL is looking forward to collaborating with Tickeri to reach diverse audiences and grow together as a company.
    • Live events have shown great excitement in 2021, with Tickeri’s numbers already surpassing those from the pre-covid period.

    HMBL’s further plans:

    Tickeri’s acquisition provides an opportunity to combine the security and transactional technology of ticketing with HUMBL’s thesis of using blockchain technology to solve global problems.

    While working with HUMBL Ticketing to expand into new markets across primary and secondary ticketing, Tickeri will continue to operate in its existing service areas.

  • How Did The RushNet (RSHN) Stock Skyrocket In The Last Session, Jumping 38%?

    RushNet Inc (RSHN) closed the last trading session at $0.0171 after seeing its market cap rise 37.90% to $132.78M. RushNet stock recently traded 1.12B shares, exceeding its average daily volume of 223.58M shares.

    Additionally, the RSHN stock has been trading between $0.0130 and $0.0190. There are 7.76 billion shares outstanding and 7.13 billion float in pink sheets. RSHN stock rose as its merger target launched a national sales campaign.

    The campaign was for what?

    RushNet is a groundbreaking company that aims to improve quality of life and longevity for people. Nutraceuticals, CBD, land, educational material and more are among RSHN’s broad range of products and trademarked brand Herbal Therapeutics. The RSHN staff includes specialists in CBD, cultivators, and healthcare specialists, making it the only company to be able to tackle a wide range of diseases at one time.

    RushNet yesterday announced that its merger/acquisition target heliosDX will be launching a National Sales Campaign.

    • As part of the deal, RSHN/helioDx will utilize Verb Technology Company, Inc.’s cutting-edge interactive platform, verbTEAMS, and verbLIVE.
    • helioDX is preparing to launch a national campaign in the near future to strengthen the brand and reach more customers.
    • By adopting verbTeams, the company gets the power to increase sales, increase closing ratios, optimize costs, and expand business across the country.
    • Through verbTeams, heliosDX is able to have an entire sales force at a fraction of the cost of traditional field sales.

    Other moves by RSHN:

    RushNet (RSHN) announced recently that heliosdDX has signed a binding letter of intent to acquire a privately held laboratory with revenue of $10,000,000 annually that processes up to 5,000 tests monthly with a capacity for 12,000 tests monthly.

    heliosDX’s presence across the country will grow thanks to this acquisition, which will also reduce costs, triple the sales force, and allow the company to process substantially more tests within the UDS portfolio. And this will eventually be benefiting for the RSHN going forward.

  • What Brought The GTT Stock Down 5% After Close Of The Market?

    In the most recent extended trading session, GTT Communications Inc. (GTT) stock fell -5.28% to $2.33. GTT closed the previous trading session at $2.46, up 20.00% or $0.41. The price of GTT stock ranged between $2.04 and $2.99.

    There were 25.95 million shares of GTT stock exchanged, higher than the company’s 50-day daily volume of 5.83 million shares and more than the Year-to-date number of 5.06 million shares. Though GTT’s stock was not affected by any significant news today, the company’s bankruptcy filing did weigh on its stock.

    Recent developments at GTT:

    GTT connects people in every organization and in every country to cloud-based solutions. Founded on the core values of simplicity, speed, and agility, GTT provides outstanding services to its clients. As a global Tier 1 provider of internet services, GTT operates an extensive network of cloud networks for its clients.

    In It appears more and more likely that corporate finance textbooks should include a chapter on memes, Bloomberg wrote on Monday.

    • US stock market participants do not seem to pay much attention to bankruptcy on the horizon.
    • It might sound like a warning about the state of investing in 2021, but reality is much stranger.
    • It seems that even explicit dire warnings are not registering.
    • Bloomberg reported May 24 that GTT is considering a bankruptcy plan that would wipe out shareholders, which is typical of Chapter 11 cases.
    • Since then, however, the company’s stock has appreciated by about 69%.

    GTT’s performance:

    The GTT stock has retreated -68.66% in the past year, and has dropped -10.87 percent over the last week. GTT stock has lost -36.76% over the last six months and has increased by 17.14% over the last three months. So far this year, GTT shares have lost -31.09%. It appears that the stock price falling in extended trades may be due to the stock consolidating after the regular session when it gained traction.

  • What Raised The Jounce (JNCE) Stock 5% Up In Extended Trading?

    As of last check in afterhours trading, Jounce Therapeutics Inc. (JNCE) was up 5.01% to trade at $7.75. During the regular session on Wednesday, shares of Jounce stock closed at $7.38, down 2.25 percent.

    On the day of trading, JNCE stock volumes were 0.72 million shares, a substantial increase over the 396.95K average daily volume over the past three months. Throughout the trading session, JNCE stock fluctuated between $7.315 and $7.75. The company is to host a virtual event this month, news that came to be raising the JNCE stock.

    What is the purpose of that event?

    With a biomarker-driven approach, Jounce is dedicated to transforming the treatment of cancer through immunotherapy therapies that enable the immune system to attack tumors and provide long-term benefits to patients.  Multiple JNCE development programs are currently underway while also advancing a number of translational science assets based on its robust discovery engine.

    Earlier today, Jounce announced it would host a virtual Research and Development Day.

    • The event will be held by JNCE on Wednesday, June 23, 2021, at 10:00 a.m. – 12:00 p.m. ET.
    • JNCE management and scientific team members will present, as well as key opinion leader and Jounce scientific founder Robert Schreiber, PhD, of The Washington University School of Medicine.
    • Those who are interested can access the webcast of the R&D Day by visiting the Investors and Media section of Jounce’s website under “Events and Presentations.”
    • A replay of the webcast will be available after the presentation for 30 days.

    Other developments:

    Jounce (JNCE) also announced this week that the US Food and Drug Administration (FDA) approved its Investigational New Drug (IND) application for JTX-1811, an anti-CCR8 antibody. The rights to develop and commercialize JNCE’s that antibody belong exclusively to Gilead Sciences, Inc. (Nasdaq: GILD). JNCE will receive a $25.0 million milestone payment upon IND clearance.

  • VINO Stock Was Down Nearly 20% In After Trades, Why?

    Gaucho Group Holdings Inc. (VINO) shares have fallen -19.55% at $6.42 in Wednesday’s after-hours session. Gaucho added 95.11 percent to close the regular trading session at $7.98. VINO stock traded 27.52 million shares, which was far above the average daily trading volume published for the last 50 days of 180.18K shares. Since it nearly doubled its value during regular trades on the day, VINO stock was consolidating in extended trading.

    Why did VINO’s value double?

    Gaucho is a real estate developer, investor, and operator in Argentina through its subsidiaries. VINO has been sourcing and developing opportunities in Argentina’s undervalued luxury real estate and consumer market for more than ten years. It is VINO’s goal to become the leading provider of multi-faceted luxury goods and experiences in prestigious lifestyle industries and online retail landscapes by taking advantage of the continued and rapid growth of e-commerce globally.

    Gaucho announced the official launch of its Amazon storefront, Gaucho-Bueno Aires. The luxury goods of Gaucho Buenos Aires will now be available via that site in addition to GauchoBuenosAires.com.

    Gaucho-Buenos Aires merged the myth and legend of the gaucho with the spirit of Buenos Aires, a city renowned for its bold and confident spirit. The leather goods, accessories, and ready-to-wear fashions at Gaucho-Buenos Aires were designed for global citizens who live authentically and are incisive in their observations of modern life.

    Does VINO stand to benefit from this?

    VINO’s ecommerce development has reached a significant milestone with Amazon Storefront. To enhance its global profile, Gaucho (VINO) is launching several new initiatives in 2021. The new Amazon Storefront will enable VINO to offer our luxury brands and products to a wider audience, while also leveraging Amazon’s reach.

  • BriaCell Therapeutics Corp. (BCTX) Stock Undergoes Volatility Ahead of Expanded Cancer Platform Technology Announcement

    BriaCell Therapeutics Corp. (BCTX) Stock Undergoes Volatility Ahead of Expanded Cancer Platform Technology Announcement

    BriaCell Therapeutics Corp. (BCTX) stock prices were up by a hefty 8.96% as of the market closing on June 16th, 2021, bringing the price per share up to USD$6.57 at the end of the trading day. After-hours trading, however, saw the stock drop by 9.28%, bringing it down to USD$5.96.

    Oncology Therapeutics

    The company announced on June 16th, 2021 the advancement of its targeted oncology therapeutics into various respective immunotherapy cell lines. Among these are Bria-Pros for prostrate cancer, Bria-Mel for melanoma, and Bria-Lung for lung cancer. The treatment was most effective in breast cancer when patient HLA-type matched with the targeted immunotherapy, owing to the potential afforded to Briacell to identify patients most likely to respond to the treatment.

    HLA-Type Testing

    This innovative approach makes use of human leukocyte antigen (HLA-type) testing, which is both simple to use and widely available, making it a highly accessible resource. With the use of its proprietary cell engineering technology, the company is now developing off-the-shelf personalized immunotherapy for various cancer indications, which utilizes the HLA-matching platform technology.

    Bria-Pros

    Bria-Pros is an off-the-shelf personalized treatment for prostate cancer, which is the second most common cancer among men in the US and one of the leading causes of cancer deaths in men. Existing treatments for metastatic prostate cancer include immunotherapy, hormone therapy, chemotherapy, and targeted treatments. However, there is much ground left to be broken in prostate cancer therapies, seeing how none of the existing ones are curative.

    Bria-Mel

    Bria-Mel is personalized immunotherapy for melanoma, with off-the-shelf availability. With more than 80,000 melanoma diagnoses being administered in the US alone, the disease claims the lives of more than 8000 patients every year. Immunotherapy, targeted therapy, and chemotherapy are options in the treatment for advanced melanoma, with there being a large unaddressed need for new safe and effective therapies for melanoma.

    Bria-Lung

    Bria-Lung is designed as personalized immunotherapy for lung cancer, being available off-the-shelf. Being the third most common type of cancer in the world, more than 130,000 Americans succumb to it every year. The most common form of lung cancer is called non-small cell lung cancer (NSCLC) and its spread (metastasis). With treatments including targeted therapies, immunotherapy, and chemotherapy, no treatment is likely to cure the cancers, indicating a large unmet need.

    Future Outlook for BCTX

    Armed with the development of accessible treatments that the company hopes will address large sections of unmet need, BCTX is poised to push for the proliferation of the treatments to expand and consolidate their market footprint. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • Why Clovis Oncology Inc. (CLVS) stock price went up on Wednesday?

    Why Clovis Oncology Inc. (CLVS) stock price went up on Wednesday?

    Clovis Oncology Inc. (CLVS) shares gained 5.58% in the after-hours on Wednesday, June 16, 2021, and closed at $6.24 per share. in the morning session, CLVS stock gained 2.43% and closed at $5.91 per share. CLVS shares have fallen 19.59% over the last 12 months, and they have moved down 6.34% in the past week. Over the past three months, the stock has gained 3.32%, while over the past six months, it has added 10.88%.

    Partial Adjournment of Annual Meeting of Stockholders

    On June 11, 2021, Clovis Oncology, Inc announced partial results and the partial Adjournment of the 2021 Annual Meeting of Stockholders.

    The Annual Meeting will resume for Proposal 2 at 8:30 a.m. Mountain Time on June 23, 2021, and will continue to be held at the St. Julien Hotel, 900 Walnut Street, Boulder, Colorado 80302.

    Participating at 2021 ASCO annual meeting

    Clovis Oncology, Inc presented four abstracts featuring data from clinical studies evaluating Rubraca and/or lucitanib and one abstract on real-world data of PARP inhibitor usage at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting which held virtually on June 4-8, 2021.

    Market Equity Offering Program

    On May 18, 2021, Clovis Oncology, Inc filed a prospectus supplement with the U.S. Securities and Exchange Commission under which it may offer and sell, from time to time, shares of its common stock having an aggregate offering price of up to $75,000,000 million through an “at-the-market” equity offering program.

    Recent financial results

    On May 5, 2021, Clovis Oncology, Inc reported financial results for the quarter ended March 31, 2021.

    Q1 2021 financial highlights

    Clovis reported total revenue of $38.1 million for Q1 2021 compared to revenues of $42.6 million in Q1 2020.

    Research and development expenses were $52.8 million for Q1 2021compared to $68.2 million for the comparable period in 2020.

    Selling, general and administrative expenses were $29.9 million for Q1 2021compared to $42.6 million for Q1 2020.

    Clovis reported a net loss of $66.3 million, or $0.64 per share for Q1 2021 compared to a net loss of $99.3 million, or $1.39 per share in Q1 2020.

    As of March 31, 2021, Clovis had $190.9 million in cash and cash equivalents.

    In Q1 2021, the company used $61.9 million net cash in operating activities compared to $82.5 million reported in Q1 2020.

    Conclusion

    As of this writing, there is no latest news so CLVS positive performance on Wednesday is a bit strange but we expect it to continue its momentum in the remaining week.